Quick Answer
AVENUE THERAPEUTICS, INC. reported Cash And Cash Equivalents At Carrying Value of $2.86 million for the year ending 2025.
- AVENUE THERAPEUTICS, INC. showed an increase of +10.1% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from AVENUE THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2015 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2016: $30.0 thousand | Q1 2017: $0.00 | Q2 2017: $34.68 million | Q3 2017: $16.05 million | Q4 2017: $11.78 million | Q1 2018: $14.96 million | Q2 2018: $8.94 million | Q3 2018: $4.80 million | Q1 2019: $29.45 million | Q2 2019: $10.46 million | Q3 2019: $8.74 million | Q1 2020: $6.57 million | Q2 2020: $5.26 million | Q3 2020: $4.33 million | Q1 2021: $1.83 million | Q2 2021: $1.12 million | Q3 2021: $585.0 thousand | Q1 2022: $1.83 million | Q2 2022: $890.0 thousand | Q3 2022: $217.0 thousand | Q1 2023: $8.24 million | Q2 2023: $1.57 million | Q3 2023: $161.0 thousand | Q1 2024: $3.19 million | Q2 2024: $4.92 million | Q3 2024: $2.60 million | Q1 2025: $3.50 million | Q2 2025: $3.33 million | Q3 2025: $3.71 million.
- Historical annual values: Fiscal year 2025: $2.86 million | Fiscal year 2024: $2.59 million | Fiscal year 2023: $1.78 million | Fiscal year 2022: $6.71 million | Fiscal year 2021: $3.76 million | Fiscal year 2020: $3.13 million | Fiscal year 2019: $8.75 million | Fiscal year 2018: $2.67 million | Fiscal year 2017: $11.78 million | Fiscal year 2016: $197.0 thousand | Fiscal year 2015: $14.0 thousand | Fiscal year 2015: $0.00.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: